India, April 1 -- image credit- shutterstock

Akums Drugs & Pharmaceuticals, a contract development and manufacturing organization (CDMO), has announced the launch of a pioneering Ripasudil-Timolol combination therapy for glaucoma treatment.

This DCGI-approved product represents a significant advancement in ophthalmic care, with Akums becoming the first Indian CDMO to receive approval for this innovative formulation.

Glaucoma ranks as the second leading cause of irreversible but preventable blindness worldwide, with India contributing to 23.5% of the global burden. The condition remains third among causes of vision impairment in India, after cataract and refractive errors. Also, Ocular hypertension is closely linked to glaucoma, many ey...